BVS-857

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBVS-857
Drug Alias NameBVS-857
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin-like growth factor I receptor agonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsInsulin ResistanceBulbo-Spinal Atrophy, X-Linked
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyDenmark +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsInsulin ResistanceBulbo-Spinal Atrophy, X-Linked

Other Information

ATC CodeN/A
Related LinksN/A